U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&P 500 also rose, gaining, 0.87% to 4,887.70.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&P 500 also rose, gaining, 0.48% to 4,868.71.
NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 38,204.88 while the NASDAQ rose 0.77% to 15,281.03. The S&P 500 also rose, gaining, 0.49% to 4,869.54.
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) shares are trading lower in Friday's premarket session after ending Thursday's session with a whopping 21.2% gain.
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market.
NeuroBo Pharmaceuticals Inc (NASDAQ: NRBO) says its DA-1726, a novel oxyntomodulin analog functioning as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist, had been shown to elicit superior weight loss efficacy compared to Semaglutide and Tirzepatide
Gainers Axcella Health Inc. (NASDAQ: AXLA) rose 71.7% to $0.7450 in pre-market trading after the company reported regulatory path to registration of AXA1125 for long COVID-19 fatigue.
